Yarchoan R, Broder S
Medicine Branch, National Cancer Institute, NIH, Bethesda, MD 20892.
J Enzyme Inhib. 1992;6(1):99-111. doi: 10.3109/14756369209041358.
Some 10 years after the first recognition of acquired immunodeficiency syndrome (AIDS) as a new syndrome, we have identified a number of molecular targets to interrupt the replicative cycle of human immunodeficiency virus (HIV), the causative agent. A number of dideoxynucleosides have been identified as having anti-HIV activity in vitro, and several of these have been found to have clinical activity in patients. In contrast, while a number of agents have been found to block viral binding to the target cell in vitro, these agents have generally not shown clear-cut evidence of clinical activity. Agents which act at a variety of steps in the HIV replicative cycle are now under development, and it is likely that we will have an increased armamentarium to fight this disease in the near future.
在首次认识到获得性免疫缺陷综合征（艾滋病）是一种新综合征约10年后，我们已经确定了一些分子靶点来阻断人类免疫缺陷病毒（HIV，病原体）的复制周期。已确定多种双脱氧核苷在体外具有抗HIV活性，其中几种已在患者中发现具有临床活性。相比之下，虽然已发现多种药物在体外可阻断病毒与靶细胞的结合，但这些药物一般未显示出明确的临床活性证据。作用于HIV复制周期各个步骤的药物目前正在研发中，在不久的将来我们对抗这种疾病可能会有更多的武器。
